Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 11/20 | 0.57 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PDE6D | O43924 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30398083 | 0.73 | MGLL (1.00) | MGLLTLR9FAAHALDH1A1HSP90AA1 | |
| SCHEMBL3768557 | 0.73 | MGLL (1.00) | MGLLTLR9FAAHALDH1A1HSP90AA1 | |
| SCHEMBL27885588 | 0.73 | HTR2A (0.60) | ALDH1A1PLK4MAPK9LIMK1CLK4 | |
| SCHEMBL27519391 | 0.73 | MGLL (0.51) | MGLLTLR9CCNE1CDK2 | |
| SCHEMBL7198015 | 0.71 | SIRT2 (0.44) | MGLLTLR9ALDH1A1NPSR1CCNE1 | |
| SCHEMBL31301648 | 0.71 | LRRK2 (0.55) | ALDH1A1HTR2ATDP1 | |
| SCHEMBL28624878 | 0.71 | MGLL (0.73) | MGLLTLR9FAAHALDH1A1HSP90AA1 | |
| SCHEMBL9374458 | 0.71 | MGLL (0.51) | MGLLTLR9FAAHHTR2A | |
| SCHEMBL13544531 | 0.69 | CLK1 (0.50) | ALDH1A1PLK4MAPK9LIMK1CLK4 | |
| SCHEMBL856333 | 0.69 | TLR9 (0.52) | MGLLTLR9ATMTDP1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819697-B1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | UNIV MAINZ JOHANNES GUTENBERG (DE) | 2012-08-01 | — | — | EP | disclosed |
| US-8008320-B2 | 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors | Johannes Gutenberg-Universitatis (DE) | 2011-08-30 | — | — | US | disclosed |
| US-20090306124-A1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-1819697-A1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | Johannes Gutenberg-Universität Mainz (DE) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006061212-A1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | Johannes Gutenberg-Universität Mainz (DE) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306124-A1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | FLT4, KDR, FLT1 | MGLL 950/4885TLR9 4601/4885FAAH 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.